A phase I/IIa study to evaluate the tolerability, safety, pharmacokinetics and efficacy of eciruciclib (BPI-1178) alone in advanced solid tumors and in combination with endocrine therapy for advanced or recurrent HR+/HER2- breast cancer.

BPI-1178 - Beta Pharma

letrozole - Generic mfg.

fulvestrant - Generic mfg.

https://meetings.asco.org/abstracts-presentations/248676/

Yiqun Du; Jiong Wu; ChangLu Hu; Wenyan Chen; Min Yan; Wei Li; Yongsheng Li; Yuee Teng; Huiping Li; Tao Huang; Yongkui Lu; Don Zhang; Jirong Peng; Feng Gao; Tingting Wang; WenXuan Zhang; Jian Zhang

Apr 23, 2025